/
FMS
$22.68-$0.02 (-0.11%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$12.5B
537M shares
52-week range
$20.02 – $28.87
30% from low
Exchange
NYSE
ADRC
Borrow rate
3.39%
Moderate
Price (6 mo)
Loading chart…
Change$-19.07
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $16.55B | $17.48B | $17.86B | $17.62B | $19.40B | $19.45B | $19.34B | $19.63B |
| Cost of revenue | $11.39B | $12.08B | $12.32B | $12.85B | $14.50B | $14.53B | $14.58B | $14.60B |
| Gross profit | $5.16B | $5.40B | $5.54B | $4.77B | $4.89B | $4.93B | $4.76B | $5.03B |
| Gross margin | 31.2% | 30.9% | 31.0% | 27.1% | 25.2% | 25.3% | 24.6% | 25.6% |
| R&D | $134.0M | $168.0M | $193.8M | $220.8M | $228.6M | $232.0M | $183.5M | $158.0M |
| Operating income | $3.04B | $2.27B | $2.30B | $1.85B | $1.51B | $1.37B | $1.47B | $1.83B |
| EBITDA | $2.91B | $3.92B | $4.13B | $3.55B | $3.42B | $3.21B | $3.21B | $3.40B |
| Net income | $1.98B | $1.20B | $1.16B | $969.3M | $673.4M | $499.0M | $537.9M | $978.4M |
| Net margin | 12.0% | 6.9% | 6.5% | 5.5% | 3.5% | 2.6% | 2.8% | 5.0% |
| EPS (diluted) | 3.23 | 1.35 | 1.31 | 0.83 | 0.57 | 0.85 | 0.92 | 1.68 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $19.7B | $2.02 | $1.90–$2.16 | 4 |
| 2027 | $20.4B | $2.21 | $2.11–$2.40 | 4 |
| 2028 | $21.2B | $2.49 | $2.45–$2.63 | 3 |
| 2029 | $22.3B | $2.98 | $2.93–$3.15 | 2 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$90.61
Price
$22.68
Implied upside
+300%
Peer comparison
Fresenius Medical Care AG
Fresenius Medical Care is the largest dialysis company in the world, treating nearly 300,000 patients from about 3,600 clinics worldwide as of December 2025. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.
www.freseniusmedicalcare.com- Employees
- 108,165
- IPO / List date
- Sep 17, 1996
Held by traders on TradeandTell
No one on the platform currently holds FMS.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in FMS as of their last filing.
Insider activity (SEC Form 4)
Dividend history
TTM yield · 10.24% ($2.32/share)
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-05-22 | $0.8643 | 2026-06-08 |
| 2025-05-23 | $0.8150 | 2025-06-06 |
| 2024-05-17 | $0.6428 | 2024-06-03 |
Stock splits
| Execution date | Ratio |
|---|---|
| 2012-12-04 | 2-for-1 |
Recent trades on TradeandTell
No one on the platform has traded FMS yet.
